

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden hours per response. . 11

Under the Securities Exchange Act of 1934  
(Amendment No. 2)\*

AVI BioPharma, Inc.

(Name of Issuer)

Common Stock, \$.0001 par value

(Title of Class of Securities)

637184 10 8

(CUSIP Number)

02/26/03

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 637184 10 8

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)  
SuperGen, Inc. 91-1841574

2. Check the Appropriate Box if a Member of a Group (See Instructions)

- (a)
- (b)

3. SEC Use Only

4. Citizenship or Place of Organization  
Delaware

Number of Shares Beneficially Owned by Each 5. Sole Voting Power  
2,634,211

6. Shared Voting Power  
0

**Reporting  
Person With**

7. **Sole Dispositive Power**  
50,000

---

8. **Shared Dispositive Power**  
0

---

9. **Aggregate Amount Beneficially Owned by Each Reporting Person**  
2,684,211

---

10. **Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)** [  ]

---

11. **Percent of Class Represented by Amount in Row (9)**  
10.1%

---

12. **Type of Reporting Person (See Instructions)**  
CO

---

2

---

**Item 1.**

- (a) **Name of Issuer**  
AVI BioPharma, Inc.
- (b) **Address of Issuer's Principal Executive Offices**  
One S.W. Columbia Street, Suite 1105, Portland, Oregon 97258

**Item 2.**

- (a) **Name of Person Filing**  
SuperGen, Inc.
- (b) **Address of Principal Business Office or, if none, Residence**  
4140 Dublin Boulevard, Suite 200, Dublin, CA 94568
- (c) **Citizenship**  
Delaware
- (d) **Title of Class of Securities**  
Common Stock, \$.0001 par value
- (e) **CUSIP Number**  
637184 10 8

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a) [  ] **Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).**
- (b) [  ] **Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).**
- (c) [  ] **Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).**
- (d) [  ] **Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).**
- (e) [  ] **An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);**
- (f) [  ] **An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);**
- (g) [  ] **A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);**
- (h) [  ] **A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);**
- (i) [  ] **A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);**
- (j) [  ] **Group, in accordance with §240.13d-1(b)(1)(ii)(J).**

**Item 4. Ownership**

**Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.**

- (a) **Amount beneficially owned:** 2,684,211 shares

(b) **Percent of class:** 10.1%, based on 26,448,045 outstanding shares of Common Stock of the Issuer as of October 31, 2002, as reported in the Issuer's last Quarterly Report on Form 10-Q filed on November 13, 2002.

3

(c) **Number of shares as to which the person has:**

- (i) **Sole power to vote or to direct the vote** 2,684,211 shares
- (ii) **Shared power to vote or to direct the vote** 0
- (iii) **Sole power to dispose or to direct the disposition of** 50,000 shares\*
- (iv) **Shared power to dispose or to direct the disposition of** 0

\* Senior Exchangeable Convertible Notes (the "Notes") were issued at face value by SuperGen, Inc. ("SuperGen") on February 26, 2003 to investors and are exchangeable, six months after the issuance of the Notes, into up to 2,634,211 shares of the Issuer's Common Stock currently held by SuperGen (the "AVI Shares"). SuperGen also pledged the AVI Shares to secure its exchange obligations under the Notes and therefore is deemed to no longer have dispositive power over the AVI Shares. A more detailed description of the transaction pursuant to which SuperGen pledged the AVI Shares is set forth in the Form 8-K filed by SuperGen on February 27, 2003.

*Instruction.* For computations regarding securities which represent a right to acquire an underlying security see §240.13d3(d)(1).

**Item 5. Ownership of Five Percent or Less of a Class**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

Not applicable.

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

4

---

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

03-17-03

**Date**

/s/ Joseph Rubinfeld

**Signature**

Joseph Rubinfeld, Chief Executive Officer, President and Chairman of the Board of SuperGen, Inc

**Name/Title**

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on

file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)**